Nasus Pharma Ltd. (NSRX) — Financial Flexibility Index

Latest as of December 2025: -2.19x

Nasus Pharma Ltd. (NSRX) has a Financial Flexibility Index of -2.19x as of December 2025. Free cash flow of $-4.90 Million (operating CF $-4.92 Million minus capex $14.00K) represents -2% of total liabilities ($2.24 Million). Check Nasus Pharma Ltd. (NSRX) tangible equity ratio to evaluate the tangible quality of the company's equity base.

Financial Flexibility Index

-2.19x
Free Cash Flow / Total Liabilities

Free Cash Flow

$-4.90 Million
Operating CF − Capex

Total Liabilities

$2.24 Million
USD

Capital Expenditures

$14.00K
USD

Nasus Pharma Ltd. Financial Flexibility Index (2022–2025)

Historical Financial Flexibility Index trend for Nasus Pharma Ltd. across 4 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Nasus Pharma Ltd..

Annual Financial Flexibility Index for Nasus Pharma Ltd. (2022–2025)

Year-by-year free cash flow to debt coverage for Nasus Pharma Ltd.. Explore how well can Nasus Pharma Ltd. service its debt to assess how comfortably operating cash covers total debt obligations.

Year Flexibility Index Free Cash Flow (USD) Operating CF Total Liabilities YoY Change
2025 -2.19x $-4.90 Million $-4.92 Million $2.24 Million ▼ -1195.8%
2024 -0.17x $-665.00K $-665.00K $3.93 Million ▲ +30.2%
2023 -0.24x $-1.03 Million $-1.03 Million $4.24 Million ▲ +35.8%
2022 -0.38x $-1.21 Million $-1.21 Million $3.20 Million
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities